Isabelle Laverdière et al. [33] found that high expression of CFH is closely related to poor prognosis for AML patients under 60 y old and even outperformed FLT3/NPM1 as a prognostic marker for intermediate-risk AML patients. This evidence concerns the gene CFH and acute myeloid leukemia.